SOURCE: Daxor Corporation

Daxor Corporation

July 07, 2010 08:30 ET

Daxor Announces That Rush University Medical Center of Chicago, IL Acquires BVA-100 Blood Volume Analyzer

NEW YORK, NY--(Marketwire - July 7, 2010) -  Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced the receipt of a signed trial agreement from Rush University Medical Center of Chicago, Illinois. This will provide Rush University with a Blood Volume Analyzer-100 (BVA-100), an instrument which enables semi-automated measurement of a patient's total blood volume, red blood cell volume and plasma volume. Blood volume abnormalities are observed in a variety of cardiac conditions and have been associated with poor prognosis.

Rush University Medical Center is a non-profit medical, educational and research center which includes a 676-bed hospital. Rush has been developing life-saving innovations and treatments for over 170 years. Its combination of research and patient care earned Rush national rankings in 9 of 16 specialty areas in U.S. News and World Report's 2009 "America's Best Hospitals" issue. Rush is home to the Heart Center for Women, the first heart program in Chicago devoted exclusively to women. In addition, the Rush Outpatient Chest Pain Center is the only center of its kind in Chicago to provide patients with a cardiac chest pain evaluation and heart attack risk assessment in a single visit. 

The treatment of Congestive Heart Failure (CHF) is a major medical expense for patients over 65 years of age, who are frequently readmitted to the hospital to receive treatment for their symptoms. Medicare is currently evaluating whether or not to withhold reimbursement for any CHF hospital readmissions which occur within 30 days of the previous hospital discharge. This will provide a strong economic incentive for hospitals to provide CHF treatments which are effective over the long-term. 

Heart failure (HF) patients with expanded blood volumes have been shown to have significantly reduced survival relative to patients with normal volume status. A 2004 study from the Columbia Presbyterian Medical Center showed a significant survival advantage for those heart failure patients who were normal or minimally hypovolemic compared to those who were hypervolemic (Am J Cardiol. 2004; 93:1254-9). These findings are important not only for their potential to improve patient outcomes, but also for their potential to reduce the financial burden of heart failure. 

Rush University Medical Center will be participating in a clinical trial (TEAM-HF) which is a follow-up to the Columbia Presbyterian study described above. Dr. Stuart Katz, who is now the Director of the Heart Failure Program at New York University, will serve as the National Principal Investigator for this multi-center study. The objective of TEAM-HF is to determine whether incorporation of blood volume results into the diagnosis and treatment of HF patients leads to decreased hospitalization and mortality, and an improvement in exercise capacity and quality of life. This trial will enroll 300 heart failure patients from 11 medical centers. If it can be demonstrated in a large-scale study that blood volume analysis leads to better patient outcomes, the BVA-100 may become a standard of care in heart failure. 

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.

Contact Information